key: cord-0777547-550q11zy authors: Ekser, Burcin; Halazun, Karim J.; Petrowsky, Henrik; Balci, Deniz title: Liver Transplantation and Hepatobiliary Surgery in 2020 date: 2020-07-19 journal: Int J Surg DOI: 10.1016/j.ijsu.2020.07.028 sha: 18b4db6bce21cadc704c8b44ff92ab2b0814549d doc_id: 777547 cord_uid: 550q11zy • It is an editorial article. No highlights. The year 2020 had a rough start with a global pandemic, the new Coronavirus Disease . The impact was so severe for long-time that many elective surgeries were cancelled, and numerous transplants were postponed, unless truly life-saving. Despite these hurdles in our daily practice, more than 100 expert academic physicians and surgeons from 22 In order to highlight the geographic variability in recent LT practices around the globe, the current status of liver transplantation in Asia [1] , North America [2] , Latin America [3] , and Europe [4] have been reviewed by international LT experts. With the aim to expand the donor pool due to the shortage of transplantable livers, LT using marginal donors (elderly livers, steatotic livers, donation after circulatory death [DCD] livers, split livers) was extensively summarized [5] . Ongoing debates in deceased donor LT (DDLT) were further discussed by experts with particular focus on limits for an acceptable DCD graft [6] , domino LT [7] , as well as the role of hypothermic [8] and normothermic machine perfusion [9] . The use of machine perfusion technology is enhancing DDLT practice, since liver grafts deemed non-transplantable due to fatty or marginal nature were rescued and successfully transplanted with assistance of machine perfusion. Another important focus of the Special Issue is dedicated to use of LT and hepatobiliary surgery to treat primary and secondary liver malignancies. The Milan criteria are the most commonly established selection criteria for LT in patients with hepatocellular carcinoma (HCC). A group of experts highlighted where we stand and what predictors we have when we perform LT in HCC patients beyond Milan Criteria [10] . In this regard, emerging biomarkers in order to predict HCC outcomes have also been highlighted [11] . One of the challenging indications for LT, cholangiocarcinoma (CCA), and its multidisciplinary treatment with or without LT has been reviewed with current developments in the field [12] . When LT is not a possibility in CCA, recently emerging surgical approach 'Associating liver partition and portal vein ligation (ALPPS)' for staged hepatectomy procedure could be life-saving [13] . ALPPS has been mainly performed for colorectal liver metastasis, and results have been steadily improving with better knowledge in how to select patients and when to proceed with stage 2 surgery [14] . Another newly introduced and developing surgical approach is LT for colorectal liver cancer metastasis [15] . A few years ago, this concept was considered an absolute contraindication to LT. However, emerging data appear to show that acceptable results can be achieved in high-risk cancer recipients with LT, far superseding survival with non-surgical approaches [15] . Although it is still experimental, the RAPID concept (i.e. resection and partial liver segment 2-3 transplantation with delayed total hepatectomy) represents another surgical innovation unifying elements of partial LT and ALPPS surgery in order to expand the donor pool [16] . The RAPID concept will LDLT is more common than DDLT in Asia [1] , and it has been increasingly performed in Turkey, Europe [4] and other parts of the world. However, many fine surgical techniques should be mastered, and many hurdles should be overcome in LDLT. Some ongoing discussions, such The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated. Please state whether Ethical Approval was given, by whom and the relevant Judgement's reference number N/A. It is an editorial. Please enter the name of the registry, the hyperlink to the registration and the unique identifying number of the study. You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study. This is mandatory for human studies only. Current status of liver transplantation in Asia Current status of liver transplantation in North America Current status of liver transplantation in Latin America Current status of liver transplantation in Europe Expanding the donor pool for liver transplantation with marginal donors Donation after circulatory death liver transplantation: what are the limits for an acceptable DCD graft? Current update in domino liver transplantation The role of hypothermic machine perfusion in liver transplantation The role of normothermic machine perfusion in liver transplantation Predictors of outcome after liver transplantation for hepatocellular carcinoma beyond Milan criteria Emerging biomarkers in hepatocellular carcinoma patients: current status Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma Associating liver partition and portal vein ligation for staged hepatectomy procedure for cholangiocarcinoma Associating liver partition and portal vein ligation for staged hepatectomy procedure for colorectal liver metastasis Liver transplantation for colorectal cancer liver metastasis Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing. Others, who have contributed in other ways should be listed as contributors.All authors contributed in writing and the development of the special issue for which we provide the editorial here. The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please note that providing a guarantor is compulsory. Not available since it is an editorial. All necessary references are cited within the text and wherever appropriate. Burcin Ekser, MD, PhD 1 , Karim J. Halazun MD 2 , Henrik Petrowsky, MD 3